- Home
- WVE
as 07-26-2024 4:00pm EST
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Upcoming Earnings Alert:
Get ready for potential market movements as Wave Life Sciences Ltd. WVE prepares to release earnings report on 01 Aug 2024.
| Founded: | 2012 | Country: | Singapore |
| Employees: | N/A | City: | SINGAPORE |
| Market Cap: | 638.0M | IPO Year: | 2015 |
| Target Price: | $13.17 | AVG Volume (30 days): | 910.5K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.50 - $7.67 | Next Earning Date: | 08-01-2024 |
| Revenue: | $112,914,000 | Revenue Growth: | 661.49% |
| Revenue Growth (this year): | -39.49% | Revenue Growth (next year): | -24.98% |
Stock Insider Trading Activity of Wave Life Sciences Ltd. (WVE)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Moran Kyle | WVE | Chief Financial Officer | Apr 3 '24 | Sell | $6.17 | 15,630 | $96,421.47 | 33,921 | SEC Form 4 |
| RA CAPITAL MANAGEMENT, L.P. | WVE | Director10% Owner | Dec 11 '23 | Buy | $5.00 | 1,000,000 | $5,000,000.00 | 19,202,009 | SEC Form 4 |
| RA CAPITAL MANAGEMENT, L.P. | WVE | Director10% Owner | Dec 11 '23 | Buy | $5.00 | 1,000,000 | $5,000,000.00 | 18,202,009 | SEC Form 4 |
| GSK plc | WVE | 10% Owner | Dec 7 '23 | Buy | $5.00 | 3,300,000 | $16,500,000.00 | 13,983,761 | SEC Form 4 |
Latest Wave Life Sciences Ltd. News
WVE Breaking Stock News: Dive into WVE Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
Analysts Are Betting On Wave Life Sciences Ltd. (NASDAQ:WVE) With A Big Upgrade This Week
MT Newswires
a month ago
Update: WAVE Life Sciences Discloses 'Positive' Phase 1b/2a Data From Huntington's Disease Treatment But Shares Fall on Neurofilament Concern
MT Newswires
a month ago
WAVE Life Sciences Discloses 'Positive' Data From Phase 1b/2a Trial of WVE-003 to Treat Huntington's Disease; Shares Rise Pre-Bell
GlobeNewswire
a month ago
Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease
BioPharma Dive
a month ago
Wave, with new data, plots path forward for Huntington’s drug
GlobeNewswire
a month ago
Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing
GlobeNewswire
2 months ago
Bangladesh Ecommerce Market Report 2024, Featuring Daraz Bangladesh, Chaldal, Evaly, Pickaboo and Ajkerdeal - Forecasts to 2028
PR Newswire
2 months ago
3 Major Product Releases at 3Shape Discover Event
Compare WVE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "WVE Wave Life Sciences Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.